TLCD5

Across TCGA pan-cancer cohorts, TLCD5 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated TLCD5 data layer compared with 1 for mutation status.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TLCD5 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TLCD5 expression acts as an unfavorable survival marker, although some lineages such as UCS and LGG show a favorable association.

ACC, UVM, and SCLC are the cancer types where TLCD5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.255	0.659	<.001	65	view →
UVM	DFS	Quartile	All	0.310	0.846	.001	59	view →
SCLC	OS	Quartile	III,IV	0.408	0.713	.004	56	view →
UCS	OS	Median	IV	0.723	0.232	.028	42	view →
LIHC	OS	Tertile	II,III,IV	0.455	0.766	<.001	42	view →
UCEC	DFS	Quartile	All	0.571	0.733	<.001	38	view →
LGG	OS	Quartile	All	0.616	0.401	<.001	33	view →
COAD	DFS	Tertile	All	0.714	0.833	.001	32	view →
CESC	DFS	Quartile	All	0.730	0.881	.001	28	view →
LUSC	OS	Tertile	III,IV	0.540	0.776	.005	21	view →
BLCA	OS	Quartile	IV	0.177	0.439	.011	18	view →
ESCA	DFS	Median	IV	0.205	0.634	.006	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

TLCD5–ACC (DFS)

Open the ACC breakdown →